- Multiethnic Asian population
- Regional clinical research hub
- Efficient regulatory process and good infrastructure
Singapore with a population of 5.8 million is an advanced English-speaking city-state on the southern tip of the Malay Peninsula.
Despite being one of the world’s smallest nations, it boasts the world’s fourth biggest financial center, and is increasingly the head office hub for international biotechs and pharmaceutical companies.
It is also regarded as the principle medical research center in South East Asia featuring highly trained HCPs, strong regulatory and ethical standards, world class healthcare comprising public and private hospitals, and six national specialty hospitals.
Healthcare in Singapore is among the world’s best. Singapore has the 4th highest life expectancy and the lowest infant mortality rate of any nation. An aging population has seen an increase in lifestyle and age-related diseases, although obesity remains low.
Novotech has established strong clinical teams in Singapore with deep local knowledge to deliver quality CRO services to biotechnology companies. In addition, it has partnered with key specialist hospital and research facilities including the Skin Research Institute of Singapore (SRIS) as part of its Partner Program, giving Novotech clients direct access to the most active and reputable KOLs, PIs and sites to facilitate study start-up and patient recruitment.
Singapore has a long history of clinical trial involvement and plays a strategic role in developing GCP in Asia as the secretariat for the APEC Coordinating Centre for Good Clinical Practice (GCP).
Clinical trials are regulated by the Health Sciences Authority (HSA) and reviewed by central or domain IRBs.
